Opinion on Biotech

Published within

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | » »|

Type Product title / description Pub Price
CommentWire
CommentWire

ICAD 2009: tau emerges as a viable target for immunotherapy in Alzheimer's

Despite being one of the two hallmarks for Alzheimer's disease for over a century, little drug development has focused on tau as a therapeutic target. At this year's International Conference for Alzheimer's Disease, two groups presented data suggesting the viability of tau as a target for vaccine development, offering an alternative target for companies keen to boost their neurology pipelines.

Published By Datamonitor
22 Jul 2009
Expert View
Expert View

ICAD 2009: beta-amyloid remains center stage at Alzheimer's disease conference

In recent years, the annual International Conference on Alzheimer's Disease has become the foremost event on the Alzheimer's disease calendar. As a primary hallmark of the disease, beta-amyloid production and deposition have become the focus for drug development. At this year's meeting progress was reported on several beta-amyloid targeted clinical stage pipeline drugs.

Published By Datamonitor
22 Jul 2009
CommentWire
CommentWire

Amgen: denosumab deal maximizes potential in tough European market

Amgen has announced that it has formed a partnership with GlaxoSmithKline to commercialize denosumab for the treatment of postmenopausal osteoporosis in Europe and emerging markets. While this partnership increases denosumab's potential in the EU, the challenge will be to convince payers that the new monoclonal antibody provides a clear clinical advantage over cheap and effective alternatives.

Published By Datamonitor
29 Jul 2009
Expert View
Expert View

Genzyme: FDA panel verdict presents setback to leukemia drug

Genzyme's plan to expand Clolar's label to include acute myeloid leukemia (AML) has been held up after an FDA advisory committee voted against its approval due to a lack of data. This news comes as a setback to Genzyme, and unless Clolar can show the desired efficacy among Genzyme's target patient population of elderly AML patients, further uptake of the drug in the clinical setting is unlikely.

Published By Datamonitor
03 Sep 2009
CommentWire
CommentWire

Amgen: Vectibix disappoints in colorectal cancer but hope remains

Amgen's Vectibix has failed to meet a secondary endpoint of overall survival in patients with KRAS wild-type metastatic colorectal cancer. This is a setback as initial positive results for the drug had suggested a strong positioning against Erbitux in the first-line. However, Vectibix did show a trend towards an improvement in survival, and Amgen may now consider further trials on this basis.

Published By Datamonitor
06 Nov 2009
CommentWire
CommentWire

Genentech/Roche: another boost for blockbuster Avastin

Roche has announced that its Genentech unit has submitted two supplemental Biologics License Applications to the FDA for Avastin in the first-line treatment of metastatic HER-2-negative breast cancer. The regulator will most likely approve Avastin for these indications on the basis of progression-free survival extension results from Phase III clinical trial data.

Published By Datamonitor
18 Nov 2009
CommentWire
CommentWire

UCB: innovative payment scheme behind Cimzia approval sets precedent in rheumatology

UCB's new rheumatoid arthritis drug, Cimzia, has been recommended for use on the NHS but only in conjunction with a company-sponsored patient access scheme. As such, UCB will cover all treatment costs for the first 12 weeks of therapy. This is a shrewd way of ensuring Cimzia's use by the cost-conscious NHS, and could herald change in both prescribing practices and future NICE submissions.

Published By Datamonitor
26 Jan 2010
CommentWire
CommentWire

Top pharmaceutical and biotech companies face slowdown in sales growth over 2008-14

A Datamonitor report has identified that the leading pharmaceutical and biotech companies face a major slowdown in sales growth out to 2014, primarily a result of the imminent patent expiries facing many blockbusters and the subsequent threat from generics. Prescription sales are expected to rise at a compound annual growth rate of just 1.2% over 2008-14, compared to a historical rate of 10.5%.

Published By Datamonitor
01 Mar 2010
Expert View
Expert View

Dendreon: landmark cancer vaccine approval but high costs may hinder uptake

Having been approved by the FDA in castration-resistant prostate cancer, Dendreon's Provenge represents the first therapeutic cancer vaccine to reach the market. This is a significant step forward: the current standard of care is Taxotere-based chemotherapy, which is associated with significant toxicity. However, it remains to be seen how frequently Provenge is used.

Published By Datamonitor
30 Apr 2010
Expert View
Expert View

Amgen promotes novel offering at World Congress on Osteoporosis

The 2010 International Osteoporosis Foundation World Congress on Osteoporosis and 10th European Congress on Clinical and Economical Aspects of Osteoporosis and Osteoarthritis in May was the most important meeting of the year in the osteoporosis arena. While no new groundbreaking data for the drug were revealed, Amgen used the congress to promote its novel monoclonal antibody denosumab.

Published By Datamonitor
18 May 2010

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | » »|

No help is available.